The treatment of childhood B-cell-precursor ALL after isolated-extramedullary or late relapse is controversial. Most approaches are based on chemotherapy or allogeneic transplantation. The aim of this report is to assess the long-term outcome of children with 'low-risk' relapsed ALL treated according to a prospective purified autotransplantation protocol. From January 1997 to March 2004, at a single pediatric Center, 30 ALL consecutive children, lacking an HLA-identical sibling, were treated according to the autologous purified peripheral blood stem cell protocol after isolated-extramedullary (7) or late medullary (24) relapse. After the 'DIAVE' mobilizing regimen a median of 11.6 Â 10 6 CD34 þ /Kg (range 3.9-27.4) were collected. Leukaphereses were depleted by 99% of CD19 þ cells (range 98-100) by means of a double step immunological purification. The conditioning regimen included TBI. No early severe complications nor transplant-related deaths occurred; late effects, as expected, mostly consisted in endocrinological issues and were assessed at a median follow-up of 8.5 years. Five-year-EFS and survival were 68.5% (s.e. 7.9) and 85.7% (s.e. 5.9), respectively, for the 35 eligible patients and 70.0% (s.e. 8.4) and 86.7% (s.e. 6.2) for the 30 patients actually transplanted as per protocol. The outcome of this series favorably compares with historical data regarding both autologous transplantation and standard salvage chemotherapy.
The benefit of allogeneic transplantation has been clearly shown for high-risk relapse of childhood ALL, which occurs early and involves the BM. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, the treatment is still controversial for low-risk relapses, which either involve extramedullary sites only and/or occur late in the BM. [10] [11] [12] [13] [14] Autologous transplantation may be an alternative to chemotherapy for ALL in CR2 after low-risk relapse. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] In 2001, we reported a study that showed the feasibility and efficacy of an innovative protocol for autologous transplantation of purified peripheral hematopoietic stem cells in 12 pediatric patients with pediatric B-cell-precursor ALL after isolated extramedullary and/or late relapse. 26 This strategy aimed to ensure the best available treatment for low-risk relapsed ALL children and to avoid the toxicity of allogeneic transplantation. In an attempt to prevent further relapse, a combined approach of immunological purification and myeloablative TBI was adopted. [27] [28] [29] [30] Minimal residual disease (MRD) at the time of stem cell collection was shown to be a relevant prognostic factor. [31] [32] [33] [34] Since then a larger patient population was enrolled in the protocol and a longer follow-up was achieved, which allowed a successful outcome to be confirmed and compared favorably with historical controls.
The aim of this report is to assess the long-term outcome of patients eligible for auto-transplantation with purified PBSC for 'low-risk relapsed' ALL in CR2.
Patients and methods

Enrollment and characteristics
From January 1997, at our Center, patients younger than 21 years, with B-cell-precursor ALL in CR2, after isolated extramedullary or late (430 months after the onset) relapse, who lacked a compatible related donor, were eligible for the autologous purified peripheral blood transplantation protocol, according to institutional guidelines. Informed consent was obtained from the parents or guardians for all patients. 26 All consecutive low-risk relapse patients are reported.
From August 2000 onward, molecular remission at the time of graft mobilization and collection, proven by MRD assessment, with a sensitivity at least of 1 Â 10
À4
, was included as an additional criterion for enrollment. Patients who were MRD-positive at the time of mobilization did not receive the mobilizing regimen and underwent allogeneic transplantation instead. All eligible patients, that is consecutive low-risk relapsed ALL lacking an HLAidentical sibling, were included in the main analysis; subanalyses of patients actually treated according to protocol and MRD status at stem cell collection are also reported.
Mobilization and collection
After CR2 attainment and consolidation according to the national Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP) protocols, [35] [36] [37] eligible patients received the mobilizing regimen consisting of the five-drug-chemotherapy 'DIAVE' (dexamethazone 5 mg/m 2 for 7 days, idarubicine 10 mg/m 2 and cytosine-arabinoside 3 g/m 2 on day 1, vincristine 1.5 mg/m 2 and etoposide 450 mg/m 2 on day 2), followed by G-CSF (10 mg/kg s.c. daily from day 5). 38 Circulating stem cell collection was scheduled when the number of CD34 þ cells approached a minimum of 0.03 Â 10 9 /L, with an optimal amount of 0.05 Â 10 9 /L in the peripheral blood. The collection target was 5.0 Â 10 6 CD34 þ cells/kg by means of one or two leukaphereses, expected at a median time of 12 days after starting the mobilizing regimen.
Manipulation of the graft
Apheretic products underwent a double-step immunological purification procedure, as described elsewhere. 26 Briefly, the first step of immunorosetting aimed to reduce the total cell count, by eliminating CD11b þ cells. The second step, using a column inserted in a SuperMACS (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) magnetic cell separator device, was performed after incubation with anti-CD19 MoAbs conjugated with paramagnetic microbeads (Miltenyi Biotec) to deplete virtually all CD19 þ cells and recover most CD34 þ cells. Final products, containing negatively selected 39 stem cells, were cryopreserved in DMSO, at a final concentration of 10%. 40 Molecular evaluation of MRD MRD was evaluated by molecular analysis of the junctional regions of rearranged TCR g or b genes, IgH or IgK genes or of the fusion gene transcripts PBX1/E2A and ETV6/CBFA2, generated by the t(1;19) and t(12;21) translocations, respectively. [31] [32] [33] [34] Molecular analysis was adopted to assess kinetics of MRD clearance in the BM after relapse, MRD negativity in leukapheretic products and the maintenance of molecular remission after transplantation in subsequent marrow aspirates sampled before collection and every 3 months up to 1 year after transplantation. MRD was retrospectively analyzed up to July 2000, after which MRD was prospectively analyzed and made available for clinical decisions.
Conditioning, infusion, post transplant course, long-term follow-up Purified products were to be reinfused after conditioning with TBI (200 cGy twice daily, days À7, À6, À5), etoposide (VP16 60 mg/kg, day À4) and CY (50 mg/kg, days À3, À2). 30 Myeloid engraftment was considered to occur on the first of three consecutive days with an absolute neutrophils count 40.5 Â 10 9 /L and platelet engraftment on the first of five consecutive days with a platelet count 450 Â 10 9 /L, sustained without transfusional support. Immunological reconstitution was assessed by infection surveillance and lymphocyte subset monitoring on a FACScan, by labeling cell samples with directly conjugated MoAbs, including anti-CD19, -CD3, -CD4, -CD8, -CD16 and -CD56. 41 Long-term follow-up visits were planned in surviving patients to assess general health, and in particular growth and endocrinological issues. [41] [42] [43] [44] [45] [46] Statistical analysis Results of the descriptive analysis are reported as mean and standard deviation or median and range, as appropriate. Height measurements are expressed as z-scores, indicating the extent of standard deviations, for each observation, either above or below the age-and gender-adjusted mean for the normal population. Specific percentiles were applied for Down syndrome patients. 47 EFS time was defined as the time from transplantation until second relapse or death, whichever occurred first, whereas survival time was until death from any cause. 48 Patients were censored at last follow-up in case no events occurred. The Kaplan-Meier estimator, with the Greenwood standard error (s.e.), was used to estimate the survival distribution and the log-rank test was used for comparison (two-tailed test, a ¼ 0.05. Follow-up was last updated on 31 October 2009. Analyses were performed by SAS and S-plus. Table 1 . At diagnosis and relapse children were treated according to the BerlinFrankfurt-Mu¨nster (BFM) Study Group concept, 6 of them in the standard arm, 27 in the intermediate arm and 1 in the high-risk arm of the AIEOP ALL 1991 (5), 1995 (24) or 2000 (5) frontline protocols; one patient was treated abroad. [35] [36] [37] [38] Mobilization, collection, purification Thirty-one patients were actually enrolled in the mobilization protocol and underwent autologous transplant.
Results
Enrollment
The other four, relapsing after August 2000, were excluded because of MRD positivity at mobilization, and underwent allogeneic transplantation from an unrelated (three) or haploidentical (one) donor while in CR2, instead. CR2 was attained at a median time of 42 days (range 9-76) after relapse. PBSC were mobilized at a median time of 80 days (range 24-151) after CR2, by means of the five-drugchemotherapy 'DIAVE' in 27 patients, 38 in block 3 of the AIEOP Rec'98 Protocol in three patients and in high-dose MTX associated with high-dose cytarabine in one patient who had failed to mobilize after DIAVE. One patient did not achieve 0.03 Â 10 9 CD34 þ /L in the peripheral blood and failed stem cell mobilization; in this child, stem cells were collected from the BM and were unfused unmanipulated. Thirty patients achieved a peak of 0.09 Â 10 9 CD34 þ cells (range 23-279) and a median of 11.6 Â 10 6 CD34 þ cells/kg (range 3.9-27.4) were collected at a median time of 12 days (range 10-21) from the start of the mobilizing regimen by means of one (18) or two (12) leukaphereses. A median of 8.1 Â 10 6 CD34 þ cells/kg (range 3.9-23.4) underwent the purification procedure; a median of 2.9 Â 10 6 CD34 þ cells/kg (range 0.8-9.0) were stored unmanipulated, as a back up in case of failure, for all but three patients. The first step of immunorosetting allowed for a one log-reduction of the total cell count, by eliminating 94.9% CD11b þ cells (range 65.1-100.0); the second step in the column, performed after incubation with anti-CD19 MoAbs, allowed for the depletion of 98.7% (range 98.2-100.0) of CD19 þ cells, with a median recovery of 72% (range 42-89) of CD34 þ cells, and a 5.6-fold enrichment, as median CD34 þ cell content was 1.4% (range 0.3-3.2) in the aphereses and 7.9% (range 1.7-24.1) in the final products. Final products contained a median of 5.3 Â 10 6 CD34 þ cells/kg (range 2.4-14.0), which were cryopreserved in DMSO, at a final concentration of 10%. The viability rate after thawing was 89% (range 68-98).
Molecular evaluation of MRD
MRD was evaluable by molecular methods in 24 of the 30 patients undergoing autologous transplantation as per protocol, as no relapse samples were available in 2 patients, referred from other centers, and no markers were found in 4 patients. As shown in Table 2 , MRD was never detectable in the whole unmodified apheretic products, within the sensitivity limits of the analysis (at least 10 À4 ); however, the leukemic contamination was clearly shown in three patients in the unwanted CD19 þ fraction, kept within the magnetic field of the depletion column. BM aspirates taken just before mobilization were constantly negative in all but four patients, three of whom were those with the positive MRD CD19 þ fraction. All four of these children relapsed.
Conditioning, infusion, post transplant course Of the 31 patients who underwent autologous transplantation, 30 according to the protocol and 1 with unpurged BM, the conditioning regimen started at a median of 18 days (range 2-41) after collection and consisted of TBI, VP16, CY for all but four patients. CY was excluded in the three patients with Down syndrome and VP16 was substituted by thio-tepa in another patient because of suspected VP16 intolerance. All the 31 patients, transplanted at a median of 5 months after relapse (range 2-8), reached myeloid engraftment (40.5 Â 10 9 /L) at a median of 12 days (range 10-16) and platelet engraftment (450 Â 10 9 /L) at 18 days (range 12-49) after infusion. Twelve patients (38%) developed skin erythema, known as 'engraftment syndrome', at a median of 9 days (range 7-17) after infusion. 49 Early complications consisted of mucositis, presenting at a median of 3 days (range 0-8) after graft infusion in 25 patients, and hemorrhagic cystitis at day þ 5 in one patient. 50 In terms of infections, no patient experienced early life-threatening infections. Fever occurred in 19 patients at a median of 4 days (range 1-19); this was of undetermined origin in 12 patients, associated with positive cultures in 2 and with positive chest CT scan in 5. Other infectious complications were pyodermitis in one patient, and self-limiting HBV hepatitis reacutization at day 8 in a previously positive patient. No patient developed CMV infection; herpes zoster occurred in 13 children at a median of 100 days (range 25-212) and required i.v. treatment in five of eight early (o100 days) cases and in one of seven late cases. In the third month, one patient was diagnosed with avascular bone necrosis and another with myocarditis, possibly of viral origin, requiring mild diuretic treatment, which was discontinued 6 months later on resolution. Median duration of hospitalization after infusion was 21 days (range 15-34); within 100 days after transplant, seven patients were readmitted once after first discharge for a median of 8 days (range 3-11), five of these for herpes zoster i.v. treatment.
Outcome
At a median follow-up of 8.5 years after transplantation, 24 of the 35 eligible patients are alive in CR2. The only patient who underwent haploidentical transplant in CR2 died 7 months after infusion, whereas 10 patients experienced second medullary (9) or extramedullary (1) relapse at a median of 19 months (range 11-65) after first relapse and 15 months (range 6-59) after autologous transplant. One of these 10 died of disease progression, 1 is alive in CR3 after chemotherapy and 8 subsequently underwent allogeneic transplantation from an unrelated (6) or haploidentical (2) donor after a reduced intensity conditioning regimen consisting of CY (50 mg/kg/day for 2 days) and thio-tepa (5 mg/kg/day for 2 days). 51 Of the eight who underwent allogeneic transplantation in CR3, four are in CR3 at a median of 70 (range 41-114) months after second transplant, three died after third relapse and subsequent secondary leukemia and one died of adenovirus infection after haploidentical transplant.
The KM estimates of 5-year probability of EFS and survival were 68.5% (s.e. 7.8) and 85.7% (s.e. 5.9), respectively, for the 35 eligible patients (Figure 1 
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Abbreviations: MRD ¼ minimal residual disease assessed by molecular analysis; ms ¼ months; NA ¼ not available; À ¼ negative; Pt # ¼ patient number; + ¼ positive; rel ¼ relapse. Minimal residual disease (MRD) was assessed for the 24 evaluable patients, for whom disease samples were available and a marker was found. Autologous grafts were analyzed in unmanipulated total cells collected by leukapheresis, CD19+ waste fractions and CD19À purified fractions. Patients were studied before mobilization and at 1, 3, 6 and 12 months after autologous transplantation. Target genes, molecular markers and method sensitivity, tested through DNA serial dilution in healthy donor DNA, are reported. In the last column, time of relapse after transplant is reported in months for patients experiencing second relapse. For the first eight patients, PCR products were placed on to nylon membranes and hybridized with {g-32 P} ATP radio-labeled probes (Dot-Blot); subsequent patients were analyzed by means of quantitative analysis with TaqMan probes.
Yrs after transplantation 
Long-term follow-up
At the time of the last follow-up, the Lansky or Karnofsky score was 100% for the 24 (21 CR2, 3 CR3) patients in long-term remission who underwent autologous transplantation as per protocol, 22 of whom were evaluated for late effects. [43] [44] [45] [46] 52, 53 Lymphocyte subset counts achieved normal ranges at the end of the first year after transplantation (Figure 3) . 41 Growth evaluations showed that mean height z-score at the time of transplant (mean 0.0; s.d. 0.99; range À1.94 to þ 1.67) was similar to the general population but decreased over time up to 6 years after transplant (mean À0.58; s.d. 1.12; range À2.82 to þ 1.65), with 25% of the patients below the 10th percentile and 13% below the 3rd one ( Figure 4) . [43] [44] [45] 54 Older children and adolescents (X11 years of age at transplant) were more likely to report normal growth whereas younger children (transplantation o11 years of age) reported the lowest percentiles. Ten of the 15 patients who were in post-puberal age at the time of the last visit were diagnosed with hypergonadotropic hypogonadism, which required hormonal replacement treatment in 7 of them (47%); 3 patients (15%) were diagnosed with hypothyroidism requiring hormonal replacement therapy, and 1 experienced a self-limiting autoimmune thyroiditis; 6 patients (30%) were diagnosed with a cataract, which required surgical treatment in two cases to date; 5 patients showed a very mild impairment at pulmonary function tests; 1 child had developed bilateral 
þ lymphocyte subsets differ according to three age groups (5-10 years; 10-16 years; 416 years). 41 Autotransplant in childhood low-risk CR2 ALL A Balduzzi et al avascular necrosis of distal femur condili before transplant, which did not jeopardize his ability to walk; one child presented with two asymptomatic exostosis.
42,45
Discussion
The EFS of 69% and survival of 86% reported for the 35 eligible patients at 5 years compared favorably with data available in the literature for B-cell-precursor ALL in CR2 after low-risk relapse. In the year 2000, the retrospective analysis of MRD data on the first 16 patients made it clear that MRD positivity at the time of mobilization or collection was invariably associated with subsequent relapse (EFS 0%). The association of MRD negativity with a favorable outcome led to only MRD-negative patients being enrolled after August 2000. The 5-year EFS of 70% and 5-year survival of 87% reported for those children who actually underwent the purified peripheral autologous transplantation protocol is promising. The 5-year EFS for children who were MRD-negative at the time of mobilization was 80% and the 5-year survival was 90%, both significantly higher than the outcomes of the MRD-positive patients.
The only subsequent events in CR2 after autologous transplant were second relapses, as no treatment-related deaths occurred. Although one might expect that a previous TBI could jeopardize the feasibility of a second transplant, this was in fact feasible in 8 of the 10 relapsed cases and reported only 1 non-leukemic death, with 4 patients eventually being rescued. Morbidity in the early post transplant course was acceptable and treatment duration was shorter than with standard salvage chemotherapy, which lasts for at least 2 years for most cooperative groups and includes cranial irradiation. Late effects were as expected in transplantation after conditioning with a TBI-containing conditioning regimen. [43] [44] [45] [46] This study compares favorably with previous experiences using chemotherapy and historical unmanipulated autografting, reporting EFS ranging from 33 to 56% for CNS relapses, 69% for any extramedullary relapse and from 41 to 61% for late relapses. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] In a previous matched-pair analysis for late medullary relapses, autologous transplantation, reporting an EFS of 41%, was of no benefit, compared with chemotherapy. 20 Patient selection may differ, as T-lineage ALL was excluded from this B-lineage ALL study. Therefore, this protocol yielded results at least as good as chemotherapy, compared with historical controls. Retrospective comparative studies between chemotherapy and transplantation are usually biased by the 'waiting time to transplant', which favors transplanted patients, who have to survive usually for at least 4 months after relapse to be enrolled and then actually transplanted. 55 Diversely, we enrolled all consecutive patients presenting with low-risk relapsed ALL in the study period and neither resistant diseases nor early deaths occurred.
Moreover, this autologous transplantation protocol was prospectively conducted in a single institution, with homogeneous eligibility criteria, treatment and support therapy. MRD-based patient selection, adopted after 2000, may have contributed to further improved results. In 2001, the retrospective evaluation of MRD in a cohort of 30 relapsed ALL patients within the ALL Rez 96 protocol by Eckert et al. 34 allowed the BFM group to show the strong prognostic impact of early high-level MRD. In our study, early MRD was available in 57% of cases. Within autotransplantation, the role of late-MRD negativity was highly predictive, as all four patients who were positive at Figure 4 Box and whiskers plot for height z-scores at diagnosis, at transplant and afterwards for the 24 patients in long-term remission after autologous transplantation of purified PBSC. The box contains observations that fall between the first and third quartiles of the patients on study; the horizontal line inside the box indicates the median, whereas the diamond indicates the mean. Whiskers extend from the edges of the box to either the extreme values or to a distance of 1.5 Â inter-quartile range from the median, which ever is smaller. Data points that fall outside the whiskers are extreme values. Horizontal lines in the graph from top to bottom, represent 97th, 90th, 10th and 3rd percentile (pct) of the normal population. mobilization eventually relapsed after transplant, despite negative graft products, suggesting that late residual leukemia could not be eradicated.
The method of purification adopted in this series met the targets of CD11b and CD19 depletion and CD34 recovery, but was laborious, time consuming and not carried out in a closed system. Consequently, in our institution, after 2005, for subsequent patients (who were not part of this series), a new single-step purification procedure was performed in a clinical-grade closed system, consisting of a CliniMACS magnetic cell separator device and anti-CD19-conjugated magnetic microbeads (Miltenyi Biotec).
Since this autologous transplant protocol was started in 1997, the results of each treatment strategy, including that of allogeneic transplantation from unrelated donors, frankly improved to the extent that in these days donor searches are activated for most low-risk relapsed ALL and allogeneic transplantation is strongly recommended for children whose MRD does not clear after induction. 4, 5, 56, 57 Nevertheless, the treatment of low-risk relapsed ALL, in the absence of compatible related donors, remains controversial. In this series, children developed the toxicity expected in auto-transplantation, which has not impaired their quality of life so far. Infertility and an increased incidence of endocrinological problems, growth impairment, early cataracts and second malignancies are expected compared with chemotherapy-treated children. [43] [44] [45] [46] 54, [58] [59] [60] It is always difficult to counterbalance the advantage of higher efficacy with the draw backs of long-term toxicity. Lower complication rates are expected for non-transplanted children, even though their treatment invariably includes cranial irradiation, which also increases the risk of brain tumors, and testicular irradiation or orchiectomy, in the event of testicular relapse. 50, 51 For children undergoing allogeneic transplantation the same TBI-related side effects are expected as in the autologous setting, but amplified by immunological complications, that is GVHD and infections because of highly impaired immune reconstitution, which are expected to increase treatment-related mortality and long-term side effects. 50, 54, [58] [59] [60] [61] An allogeneic approach could be adopted for children who experience relapse after autologous transplant, such as the eight patients in this series, of whom four were rescued and are in long-term CR3.
These findings would justify a randomized trial. Nevertheless, randomization between transplantation and chemotherapy is hardly feasible and likely to fail, as shown earlier by other groups in the same or different settings. 62, 63 Treatment assignment in ongoing ALL relapse trials is mostly MRD based; chemotherapy plus cranial irradiation is planned for patients with MRD levels lower than 1 Â 10 3 (low risk) after induction and allogeneic transplantation for those with MRD levels higher than 1 Â 10 3 (high risk), whose EFS would be lower than 20% with chemo/ radiotherapy only. 34, 64, 65 Assessing the best available treatment for ALL in CR2 and defining the role of autologous transplantation is beyond the purpose of this study. The purified autologous transplantation approach deserves consideration, together with other treatment options. Among low-risk relapsed ALL children, those with early MRD negativization after relapse may be cured with chemo-and radio-therapy only; those with persistently positive MRD would need an allograft to be cured; those with positive MRD after induction but who achieve MRD negativity in the subsequent 2 months may be cured by this approach.
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